U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C14H18O3
Molecular Weight 234.2909
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of STIRIPENTOL

SMILES

CC(C)(C)C(O)\C=C\C1=CC2=C(OCO2)C=C1

InChI

InChIKey=IBLNKMRFIPWSOY-FNORWQNLSA-N
InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+

HIDE SMILES / InChI
Molecular Formula C14H18O3
Molecular Weight 234.2909
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 1
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000664/WC500036518.pdf

Stiripentol is an anticonvulsant drug used in the treatment of epilepsy. It recently proved to increase the GABAergic transmission in vitro in an experimental model of immature rat. Clinical studies were based on the fact that STP also acts as an inhibitor of CYP3A4, CYP1A2, and CYP2C19 in vivo in epileptic patients. Side effects are largely due to the increase in plasma concentrations of other anticonvulsants and can be reduced by lowering the dose of those drugs. Nausea and vomiting are particularly noted when used in combination with sodium valproate. It appears to increase the potency of phenobarbital, primidone, phenytoin, carbamazepine, clobazam and diazepam.

CNS Activity

CNS Active
3913
Curator's Comment: Known to be CNS penetrant in rats. Human data not available.

Originator

BIOCODEX
1
Curator's Comment: The product was first identified by BIOCODEX, in 1978 with early clinical development starting in 1980s.

Approval Year

2018
436
Targets

Targets

Primary TargetPharmacologyConditionPotency
Modulator
828
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Diacomit

Approved Use

It is indicated for treating severe myoclonic epilepsy in infancy (SMEI, also know as Dravet's syndrome).

Launch Date

1.00742398E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
6.5 mg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24725808/
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
STIRIPENTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2.1 mg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24725808/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
STIRIPENTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
14 mg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24725808/
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
STIRIPENTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
31 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24725808/
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
STIRIPENTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
8.3 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24725808/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
STIRIPENTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
88 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24725808/
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
STIRIPENTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.7 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24725808/
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
STIRIPENTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24725808/
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
STIRIPENTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
10 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/24725808/
2000 mg single, oral
dose: 2000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
STIRIPENTOL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 6
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 6
Disc. AE: Status epilepticus, Drowsiness...
AEs leading to
discontinuation/dose reduction:
Status epilepticus (< 1%)
Drowsiness (< 1%)
Balance impaired NOS (< 1%)
Sialorrhea (< 1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 6
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (15%)
Vomiting (9%)
Salivary hypersecretion (6%)
Fatigue (9%)
Pyrexia (6%)
Bronchitis (6%)
Nasopharyngitis (6%)
Weight decreased (27%)
Weight increased (6%)
Decreased appetite (46%)
Somnolence (67%)
Ataxia (27%)
Hypotonia (18%)
Tremor (15%)
Dysarthria (12%)
Agitation (27%)
Insomnia (12%)
Aggression (9%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
AEs

AEs

AESignificanceDosePopulation
Balance impaired NOS < 1%
Disc. AE
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 6
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 6
Drowsiness < 1%
Disc. AE
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 6
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 6
Sialorrhea < 1%
Disc. AE
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 6
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 6
Status epilepticus < 1%
Disc. AE
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 6
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 6
Dysarthria 12%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Insomnia 12%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Nausea 15%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Tremor 15%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Hypotonia 18%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Agitation 27%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Ataxia 27%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Weight decreased 27%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Decreased appetite 46%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Bronchitis 6%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Nasopharyngitis 6%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Pyrexia 6%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Salivary hypersecretion 6%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Weight increased 6%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Somnolence 67%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Aggression 9%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Fatigue 9%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Vomiting 9%
50 mg/kg 1 times / day steady, oral
Recommended
Dose: 50 mg/kg, 1 times / day
Route: oral
Route: steady
Dose: 50 mg/kg, 1 times / day
Co-administed with::
clobazam
valproate
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
unhealthy, mean age 9.2 years
n = 33
Health Status: unhealthy
Condition: Dravet syndrome
Age Group: mean age 9.2 years
Sex: M+F
Population Size: 33
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206709s000,207223s000lbl.pdf
Page: 7
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inducer
781
substrate
1037

inhibitor
1767
substrate
1217

inhibitor
1852

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2B6
810

CYP2C19
1478

CYP2C8
911

CYP3A
214

P-gp
1461

BCRP
699

OATP1B1
788

OATP1B3
706

OAT1
599

OAT3
642

OCT2
647
CYP1A2
1054

CYP2C19
991

CYP3A5
395

UGT
192

P-gp
1537

BCRP
561

OATP1B1
406

OATP1B3
350

OAT1
326

OAT3
339

OCT2
355
CYP1A2
701

CYP2B6
547
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1819
 no [IC50 130 uM]
CYP2D6
1891
 no
OAT1
603
 not significant
OAT3
644
 not significant
OATP1B1
803
 not significant
OATP1B3
715
 not significant
OCT2
648
 not significant
CYP3A
298
 yes [IC50 13 uM]
CYP2B6
1001
 yes [IC50 14 uM]
BCRP
773
 yes [IC50 2.34 uM]
CYP1A2
1692
 yes [IC50 6.6 uM]
CYP2C8
965
 yes [IC50 6.8 uM]
CYP2C19
1553
 yes [IC50 9.2 uM]
P-gp
1650
 yes [IC50 92.1 uM]
CYP1A2
1692
 yes
CYP2B6
1001
 yes
CYP3A4
1925
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
BCRP
561
 no
OAT1
326
 no
OAT3
339
 no
OATP1B1
406
 no
OATP1B3
350
 no
OCT2
355
 no
P-gp
1537
 no
CYP1A2
1054
 yes
CYP2C9
1037
 yes
CYP2D6
1217
 yes
CYP3A5
395
 yes
UGT
192
 yes
CYP2C19
991
 yes
yes (co-administration study)
Comment: Co-administration of clobazam (CYP3A4 substrate) with stiripentol increased concentrations of clobazam by approximately 2-fold and norclobazam (clobazam active metabolite, CYP2C19 substrate) by 5-fold
Page: 14.0
CYP3A4
1737
 yes
yes (co-administration study)
Comment: Co-administration of clobazam (CYP3A4 substrate) with stiripentol increased concentrations of clobazam by approximately 2-fold and norclobazam (clobazam active metabolite, CYP2C19 substrate) by 5-fold
Page: 14.0
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P00D9HB
1PlusChem LLC
1P01DMPG
A2B Chem
AG18015
AA Blocks
AA00D8XV
AK Scientific
8269AH
Alfa Chemistry
ACM49763964
Angene
AGN-PC-0510R6
ApexBio Technology
A8704
AstaTech
W10731
BLD Pharm
BD151952
BOC Sciences
1185239-64-8
BOC Sciences
49763-96-4
Cayman Chemical
17781
Chem Scene
CS-7801
Combi-Blocks
QN-0342
Compound Cloud
5311454
Fluorochem
505617
Hangzhou Yuhao Chemical Technology
RT15516
Lab Network
LN01301989
Lab Network
LN01745578
Lab Seeker
SC-53649
MedChem Express
HY-103392
MolPort
MolPort-005-942-442
Molnova
M18654
MuseChem
R064217
Selleck Chemicals
S5266
ShangHai Biochempartner
BCP10434
Sigma Aldrich
S6826
Sigma Aldrich
S6826|SIGMA
StruChem
SC-53649
TargetMol
T4498
Tetrahedron
TS25569
Toronto Research Chemicals
S686825
WuXi AppTec
WX692001
ZINC
ZINC000000000724
http://zinc15.docking.org/substances/ZINC000000000724
ZINC
ZINC000002005958
http://zinc15.docking.org/substances/ZINC000002005958
ZINC
ZINC000011726811
http://zinc15.docking.org/substances/ZINC000011726811
ZINC
ZINC000022066531
http://zinc15.docking.org/substances/ZINC000022066531
eMolecules
300095130
eMolecules
36550241
eMolecules
48856676
eMolecules
50580450
mcule
MCULE-1878244070
mcule
MCULE-5305607439
PubMed

PubMed

TitleDatePubMed
Infant monkey hyperexcitability after prenatal exposure to antiepileptic compounds.
1996 Oct
Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures.
1999 Sep
Stiripentol.
2005 Jul
Patents

Patents

EP0501889 A2
1
US5095033 A
1

Sample Use Guides

In Vivo Use Guide
Initial dose is 50 mg/kg per day. This may be increased up to 100 mg/kg per day, with a maximum of 4 g/day.
Route of Administration: Oral
In Vitro Use Guide
stiripentol was found to reduce synaptosomal GABA uptake (IC50 5x10-5) and to slightly increase (+22%) brain concentrations of GABA after “in vivo” administration (300 mg/kg i.p.).
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:15:39 UTC 2023
Edited
by admin
on Fri Dec 15 19:15:39 UTC 2023
Record UNII
R02XOT8V8I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
STIRIPENTOL
EMA EPAR   INN   MART.   MI   USAN   WHO-DD  
USAN   INN  
Official Name English
BCX-2600
Code English
STIRIPENTOL [MI]
Common Name English
STIRIPENTOL [MART.]
Common Name English
Stiripentol [WHO-DD]
Common Name English
STIRIPENTOL [USAN]
Common Name English
DIACOMIT
Brand Name English
STIRIPENTOL [ORANGE BOOK]
Common Name English
1-(1,3-BENZODIOXOL-5-YL)-4,4-DIMETHYL-1-PENTEN-3-OL
Systematic Name English
BCX 2600
Code English
STIRIPENTOL [EMA EPAR]
Common Name English
stiripentol [INN]
Common Name English
STIRIPENTOL [JAN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 800820
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
EU-Orphan Drug EU/3/01/071
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
WHO-VATC QN03AX17
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
NCI_THESAURUS C264
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
EMA ASSESSMENT REPORTS DIACOMIT (AUTHORIZED: MYOCLONIC EPILEPSY, JUVENILE)
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
FDA ORPHAN DRUG 266108
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
WHO-ATC N03AX17
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
Code System Code Type Description
DRUG CENTRAL
2480
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
MERCK INDEX
m10218
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY Merck Index
CAS
137767-55-6
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
FDA UNII
R02XOT8V8I
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
RXCUI
2054968
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
INN
3760
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
EPA CompTox
DTXSID6049068
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
CAS
131206-47-8
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
SUPERSEDED
MESH
C021092
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
CAS
49763-96-4
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
NON-SPECIFIC STEREOCHEMISTRY
LACTMED
Stiripentol
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
SMS_ID
100000089171
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
WIKIPEDIA
STIRIPENTOL
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
IUPHAR
5469
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
ChEMBL
CHEMBL1983350
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
DAILYMED
R02XOT8V8I
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
EVMPD
SUB10654MIG
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
DRUG BANK
DB09118
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
ECHA (EC/EINECS)
256-480-9
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
NCI_THESAURUS
C152433
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
PUBCHEM
5311454
Created by admin on Fri Dec 15 19:15:39 UTC 2023 , Edited by admin on Fri Dec 15 19:15:39 UTC 2023
PRIMARY
Related Record Type Details
CYTOCHROME P450 2C19
METABOLIC ENZYME -> INHIBITOR
MULTIDRUG RESISTANCE PROTEIN 1
TARGET -> INHIBITOR
IC50
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TARGET -> INHIBITOR
IC50
CYTOCHROME P450 1A2
METABOLIC ENZYME -> INHIBITOR
Structure of STIRIPENTOL, (+)-
ENANTIOMER -> RACEMATE
CYTOCHROME P450 2C9
METABOLIC ENZYME -> INHIBITOR
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
Structure of STIRIPENTOL, (-)-
ENANTIOMER -> RACEMATE
PLASMA PROTEIN FRACTION
BINDER->LIGAND
Stiripentol binds extensively to circulating plasma proteins (about 9
Related Record Type Details
Structure of 1-(3-HYDROXY-4-METHOXYPHENYL)-4,4-DIMETHYL-1-PENTEN-3-OL
METABOLITE INACTIVE -> PARENT
Recovery of meta-hydroxy metabolite from urine after deglucuronization; urine was accumulated for 12hr after a single oral dose of 600mg (a single subject); Recovered metabolites total: 439.8mg
IN-VIVO
URINE
Structure of 5-(3-HYDROXY-4-METHOXYPHENYL)-2,2-DIMETHYL-4-PENTENE-1,3-DIOL
METABOLITE INACTIVE -> PARENT
<6.0mg; Recovery of Metabolite VII from urine after deglucuronization; urine was accumulated for 12hr after a single oral dose of 600mg (a single subject); Recovered metabolites total: 439.8mg
IN-VIVO
URINE
Structure of 1-(3-HYDROXY-4-METHOXYPHENYL)-4,4-DIMETHYL-3-PENTANONE
METABOLITE INACTIVE -> PARENT
Recovery of Metabolite X from urine after deglucuronization; urine was accumulated for 12hr after a single oral dose of 600mg (a single subject); Recovered metabolites total: 439.8mg
IN-VIVO
URINE
Structure of 1-(3-METHOXY-4-HYDROXYPHENYL)-4,4-DIMETHYL-1-PENTEN-3-OL
METABOLITE INACTIVE -> PARENT
trace amount from one subject
IN-VIVO
FECAL
Structure of 1-(3-METHOXY-4-HYDROXYPHENYL)-4,4-DIMETHYL-1-PENTEN-3-OL
METABOLITE INACTIVE -> PARENT
Recovery of para-hydroxy metabolite from urine after deglucuronization; urine was accumulated for 12hr after a single oral dose of 600mg (a single subject); Recovered metabolites total: 439.8mg
IN-VIVO
URINE
Structure of STIRIPENTOL GLUCURONIDE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 1-(3,4-DIHYDROXYPHENYL)-4,4-DIMETHYL-1-PENTEN-3-OL
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 5-(3-METHOXY-4-HYDROXYPHENYL)-2,2-DIMETHYL-4-PENTENE-1,3-DIOL
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 1-(3-HYDROXY-4-METHOXYPHENYL)-4,4-DIMETHYL-1-PENTEN-3-OL
METABOLITE INACTIVE -> PARENT
IN-VIVO
FECAL
Structure of STIRIPENTOL GLUCURONIDE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 1-(3.4-DIHYDROXYPHENYL)-4,4-DIMETHYL-3-PENTANONE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 5-(3,4-DIHYDROXYPHENYL)-2,2-DIMETHYL-4-PENTENE-1,3-DIOL
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 5-(3-METHOXY-4-HYDROXYPHENYL)-2,2-DIMETHYL-4-PENTENE-1,3-DIOL
METABOLITE INACTIVE -> PARENT
Recovery of Metabolite VIII from urine after deglucuronization; urine was accumulated for 12hr after a single oral dose of 600mg (a single subject); Recovered metabolites total: 439.8mg
IN-VIVO
URINE
Structure of 1-(3.4-DIHYDROXYPHENYL)-4,4-DIMETHYL-3-PENTANONE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 1-(3-METHOXY-4-HYDROXYPHENYL)-4,4-DIMETHYL-3-PENTANONE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 1-(3.4-DIHYDROXYPHENYL)-4,4-DIMETHYL-5-HYDROXY-3-PENTANONE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 1-(3-HYDROXY-4-METHOXYPHENYL)-4,4-DIMETHYL-3-PENTANONE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 1-(3.4-DIHYDROXYPHENYL)-4,4-DIMETHYL-5-HYDROXY-3-PENTANONE
METABOLITE INACTIVE -> PARENT
Recovery of Metabolite XII from urine after deglucuronization; urine was accumulated for 12hr after a single oral dose of 600mg (a single subject); Recovered metabolites total: 439.8mg
IN-VIVO
URINE
Structure of 5-(3-HYDROXY-4-METHOXYPHENYL)-2,2-DIMETHYL-4-PENTENE-1,3-DIOL
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 1-(3,4-DIHYDROXYPHENYL)-4,4-DIMETHYL-1-PENTEN-3-OL
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 1-(3-METHOXY-4-HYDROXYPHENYL)-4,4-DIMETHYL-3-PENTANONE
METABOLITE INACTIVE -> PARENT
Recovery of Metabolite XI from urine after deglucuronization; urine was accumulated for 12hr after a single oral dose of 600mg (a single subject); Recovered metabolites total: 439.8mg
IN-VIVO
URINE
Structure of 1-(3-HYDROXY-4-METHOXYPHENYL)-4,4-DIMETHYL-1-PENTEN-3-OL
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 5-(3,4-DIHYDROXYPHENYL)-2,2-DIMETHYL-4-PENTENE-1,3-DIOL
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Structure of 1-(3-METHOXY-4-HYDROXYPHENYL)-4,4-DIMETHYL-1-PENTEN-3-OL
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
Related Record Type Details
Structure of STIRIPENTOL
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
log P CHEMICAL
Tmax PHARMACOKINETIC FED CONDITIONS

ORAL

Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966